Journal of Oncology Pharmacy Practice

Aims & Scope

Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).

Publishing pertinent case reports and consensus guidelines that drive clinical practice, this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research.

As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains regular updates on ISOPP activities, as well as practical issues relating to oncology pharmacy and worker safety.

View Aims & Scope

---

Metrics & Ranking

SJR (SCImago Journal Rank)

Year	Value
2024	0.424

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	47

Journal Rank

Year	Value
2024	13271

Journal Citation Indicator

Year	Value
2024	1121

Impact Factor

Year	Value
2024	1.00

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

  Citation: 278

  Authors: Chipman RG, Aparna, Cynthia, Abdul R, Nitika, Srikala, Sulochana, Teresa, Jessica, Paul

• Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance

  Citation: 137

  Authors: Hamdan S, Sameer E, Abdel-Moneim M

• Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature

  Citation: 126

  Authors: George, Mary, Susan, Trudi, Debbie, Esther, Brent

• Management of hand-foot syndrome induced by capecitabine

  Citation: 124

  Authors: Sarah M, Brad L, Fred

• Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

  Citation: 123

  Authors: Nicole M, Vernon M, Christopher J, Anita, Rebecca, Jeffrey, Joseph J

• Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device

  Citation: 118

  Authors: Paul JM, Thomas H, James A, Timothy G

• Chemotherapy induced diarrhea

  Citation: 106

  Authors: Gillian, Roxanne

• Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings

  Citation: 93

  Authors: R Donald, Val R, Tyler, Patrick

• Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia

  Citation: 90

  Authors: Veena S, Lata, Kiran, PS, Rakesh, Rakesh

• Preface

  Citation: 84

  Authors: Thomas, Robert, Johan

---